Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAME 2 Kidney
ACTRN12625001170415Phase 3Not yet recruiting
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Fenofibrate with Placebo (2 arms). Primary endpoint: Change in estimated GFR from baseline to end of 8-week washout period. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
fenofibrate
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12625001170415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001170415.